Endo Diversifies Further With Purchase Of Qualitest for $1.2 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
By buying the sixth-largest generics firm in the U.S. Endo gets what it says is critical mass in the U.S. generics market and significant domestic manufacturing capability.
You may also be interested in...
Endo CEO Reveals Glimpse Of New Strategy: Highlights Generics Potential
During Endo’s first quarter sales and earnings call, new CEO Rajiv De Silva said his strategic review of the specialty pharma is still underway but offered investors some initial thoughts on his plans for the company.
After Spate of Transformative Acquisitions, Endo Reports Robust Growth for 1H 2011
Endo's blended business model appears to be paying off in the near term as the company raises guidance for 2011, driven by the acquisition of American Medical Systems in June and strength in its core franchises.
After Spate of Transformative Acquisitions, Endo Reports Robust Growth for 1H 2011
Endo's blended business model appears to be paying off in the near term as the company raises guidance for 2011, driven by the acquisition of American Medical Systems in June and strength in its core franchises.